Tissue Regenix Group plc
DermaPure® secures first GPO contract in US
York, 1 July 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that Tissue Regenix Wound Care, Inc. has secured a contract agreement with a national US Group Purchasing Organization (GPO) for the use of DermaPure®.
A GPO negotiates contracts and pricing with an Integrated Delivery Network (IDN) on behalf of its members which can include; regional alliances, hospitals and individual physician offices.
Effective from today, Tissue Regenix Wound Care Inc. secured a 3-year contract agreement with a national GPO which spans across 43 states and is affiliated with 48 IDNs, with a membership comprised of more than 800 acute care hospitals, 186 different Health Systems and more than 1000 long-term care facilities. This agreement now makes it easier for physicians within these facilities to access DermaPure® for the treatment of their patients.
Greg Bila, President Tissue Regenix Wound Care, Inc. commented: 'This first GPO agreement marks another significant milestone for DermaPure®, allowing a multitude of care settings and physicians to access the product. The results and clinical support that we have seen, to date, has been outstanding and we are pleased to be able to convert this into further market penetration and availability.'
For more Information:
Tissue Regenix Group plc Caitlin Pearson Corporate Communications Officer |
Tel: 0330 430 3073 |
Jefferies International Ltd Simon Hardy / Harry Nicholas |
Tel: 020 7029 8000 |
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.
